Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $90 price target on the stock.
May 08, 2024 | 9:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Intra-Cellular Therapies with a maintained $90 price target.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst like Ami Fadia can instill confidence in investors and potentially drive the stock price up in the short term. The specific mention of a $90 price target suggests a significant upside potential from the current trading price, assuming the market aligns with the analyst's valuation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100